A new report has demonstrated that siponimod (also known as BAF312 or Mayzent) can stop disability from getting worse for up to five years, in patients with secondary progressive MS.
Siponimod (Mayzent) is a tablet developed for secondary progressive MS by Novartis Pharmaceuticals. Earlier this year it was given a European license for people with active secondary progressive MS. ‘Active’ means you’ve been having relapses, or MRI scans of your brain or spinal cord show you have new lesions.
The new data came from an extension to a trial called EXPAND, which includes 1,651 people with secondary progressive MS across 31 countries. It shows that people with secondary progressive MS who are continuously treated with siponimod experienced a lower risk of disability getting worse and cognitive decline, compared to patients who delayed siponimod treatment.
How does siponimod (Mayzent) work?
Siponimod (Mayzent) works in a similar way to the licensed treatment fingolimod.
It traps certain types of immune cell (called B and T cells) in the body's lymph nodes. This stops them from getting into the brain and spinal cord, where they could cause damage to the protective myelin coating around the nerves. You can read more information about siponimod here.
When will it be available on NHS?
The National Institute of Health and Care Excellence (NICE) have been reviewing siponimod (Mayzent) and they will make a decision about whether the drug can be made routinely available on the NHS in England and Wales. We would expect similar decision to be made in Scotland and Northern Ireland at a later date.
This process has been paused for now, because NICE are currently focusing on supporting the NHS through the COVID-19 outbreak. When this process resumes, we will update you on NICE’s assessment. To keep up to date you can sign up to The Buzz, our fortnightly email with all the latest updates on MS treatments, coronavirus and support.
Help stop MS
Our Stop MS Appeal is raising £100 million for research to find treatments that stop or slow MS progression. By 2025 we want to have new treatments for everyone in the final stage of testing. But we need your help.